Discussion Board (Corporates)
 Board
Write new posting
Read old postings (archive)
Read your postings
Last 50 Postings | Last 100 Postings
11-04-25 savo
crypto carnage
I hope to see Saylor cleaned. |
|
11-04-25 savo
| How many dead people has this man caused? |
|
11-04-25 victor
| Former Vice President Dick Cheney dead at 84 |
|
11-03-25 spal
KNOT Offshore Partners rises on $10/unit buyout offer from Knutsen NYK
Nov. 03, 2025 8:34 AM ETKNOT Offshore Partners LP Common Units (KNOP) StockBy: Arundhati Sarkar, SA News Editor
KNOT Offshore Partners (KNOP) on Monday said that it received an unsolicited, non-binding offer from Knutsen NYK Offshore Tankers AS to buy all publicly traded units of the partnership for $10 cash per unit through a wholly owned subsidiary.
KNOT has proposed that a transaction would be effectuated through a merger between the Partnership and a subsidiary of KNOT.
The conflicts committee of the KNOP board, comprised of only non-KNOT-affiliated directors, will retain advisors and will evaluate the offer, the company said.
KNOT Offshore Partners (KNOP) up 9% in early trading. |
|
11-03-25 pillz
Pfizer and Novo clash in billion-dollar battle over obesity researcher
Due to the bidding of the two giants, the price tag for obesity researcher Metsera has risen from 2 billion at the beginning of this year to potentially 9 billion dollars.
The majority of investors on Wall Street had already gone home on Friday evening when Pfizer dropped a bombshell: the American pharmaceutical giant is filing summary proceedings against biotech company Metsera and the Danish pharmaceutical player Novo Nordisk
In the second clinical trial phase, Metsera is developing an obesity drug under the working name MET-097i that can be administered via a monthly injection. The company also has two obesity pills in an early research phase and is thus a dream target for Pfizer, which had to pull the plug on its own obesity research - the slimming pill danuglipron - in April after disappointing results.
In September, Pfizer had made a deal with Metsera: the shareholders of the latter would immediately receive 47.5 dollars per share or 4.9 billion dollars. An additional $22.5 per share may be added later, depending on the later research results on MET-097i in particular, which could raise the price tag to $7.2 billion.
At the end of last week, Novo Nordisk suddenly thwarted those plans with its own tiered offer: shareholders will immediately receive 56.5 dollars per share in cash, or 6.5 billion dollars. With the promise that the payout could rise to $77.75 per share or $9 billion if a number of clinical and regulatory milestones are met. At the beginning of this year, investors only valued Metsera at 2 billion dollars.
Pfizer disputes in the lawsuit filed on Friday that Metsera's board of directors can describe the Novo offer as "superior" and thus unilaterally terminate the previous takeover agreement. According to Pfizer, it is very unlikely that Novo Nordisk can quickly guide a deal past the American cartel watchdog, while the American company says it already has that green light in its pocket. Whereupon Metsera announced late Friday night in a petty press release from one line that it disagreed with Pfizer's allegations.
The clock is now ticking for Pfizer. Unless the commercial court blocks Novo Nordisk, the Americans only have until Tuesday, November 4, to either improve their own bid or abandon the bid. Pfizer CEO Albert Bourla, who according to business newspaper The Wall Street Journal is personally driving the takeover file, described Novo Nordisk's counteroffer as "reckless" in an unusually sharp press release on Thursday. The Greek-American Pfizer CEO, who previously negotiated a deal on pharmaceutical prices with US President Donald Trump, also did not hesitate to play the American card: 'This is an attempt by a dominant player to circumvent cartel law by taking over an American challenger'.
There is a lot at stake for both pharmaceutical giants. Novo Nordisk is suffering from pressure from cheaper copycat versions of players such as Hims & Hers Health with its obesity drug Wegovy, while at the same time the American Eli Lilly is taking market share with obesity drug Zepbound.
At Pfizer, Bourla is under pressure to fill the patent cliff later this decade. Blockbusters such as blood thinner Equilis and cancer drugs Ibrance and Xtandi will lose patent protection by 2028, so having an obesity drug on the market by then would be very welcome. At the same time, Pfizer is seeing sales of the 'game-changer vaccine' Comirnaty, with which the group rid the world of Covid-19 at the end of 2020, decline rapidly. In fiscal year 2024, there was a halving in sales to $5.35 billion. |
|
11-03-25 pillz
U.S. dollar bonds rebounded slightly on increased U.S. military pressure
Sun Nov 02 19:23:51 2025 EDT
The growing geopolitical tension between the US and Venezuela, fueled by reports of possible US military plans against targets in Venezuela, generated a slight but noticeable rally in the price of Venezuelan dollar-denominated bonds on Friday, October 31.
The debt instruments, which are trading at deeply depressed levels, registered a generalized upward trend in a day marked by volatility and speculation, according to the international news agency Bloomberg.
The market closed the weekwith strong upward oscillations, suggesting that some investors see the US military pressure as a factor that could accelerate a political or economic change in the country, which theoretically would increase the possibilities of an eventual debt agreement or restructuring.
The Pdvsa 2022 bond climbed to 26.74%, a significant rise from its recent historical low. Meanwhile, the VENZ 2022 closed at 29.35%, also surpassing its previously recorded lows.
Among the longer term securities, the Pdvsa 2027 closed at 22.88% and the VENZ 2027 reached 30.65%.These movements came after media outlets such as The Wall Street Journal and The Miami Herald quoted US officials and sources close to the issue, indicating that the Trump administration had identified Venezuelan military installations as possible targets for military operations aimedat combating drug trafficking.
Geopolitical momentum
In a parallel move underscoring the market's sensitivity to the Venezuelan crisis, it also spiked. The risk of a disruption in the supply of Venezuelan heavy crude oil, vital for some refineries in the Gulf of Mexico, pushed prices higher.
According to Bloomberg, volatility in the energy market is being driven directly by these geopolitical tensions.
Hours after reports of possible attacks circulated, President Donald Trump categorically denied he was responding with a simple "No" to reporters. However, this statement comes in a context where Trump had already suggested a possible "ground intervention" the previous week, keeping uncertainty and risk premium on Venezuelan assets.
The rally in bonds, although significant in percentage terms, continues to keep them at "extreme risk" levels, reflecting the sovereign and PDVSA default, and Venezuela's deep political and economic complexities. The debt market, for now, seems to be pricing in the escalating international pressure as a potential catalyst.
SID(FNWc91dd00f918d1df6f68e)
dvpcoz gcat gdip gpir i1 ifosfl iioil ioilgas lamz namz samz usa ven
Provided by INTERCONTINENTAL EXCHANGE INC
**M2Z-PR-ESCS-08 |
|
|
